Æterna Zentarisの収益YQ/Q
Æterna Zentarisの収益YQ/Qは何ですか。
Æterna Zentaris, Inc.の収益YQ/Qは-99.81%です。
収益YQ/Qの定義は何ですか。
四半期収益成長率、前年比は、前年同期の業績と比較して、売上高の増加率がパーセンテージとして表されています。
Quaterly revenue growth is the amount by which revenue exceeds the revenue in a previous quarter. It is beneficial to look at a company's quarterly financials to identify how the company is performing over time not just during the current period. The usage of year over year comparison is advantageous in removing seasonalities in reporting the quarterly revenue growth and observing longterm trends.
TSXのセクタHealth Careにおける収益YQ/Qの企業と比べるÆterna Zentaris
Æterna Zentarisは何をしますか。
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Æterna Zentarisと類似の収益yq/q
- Micron Solutionsの収益YQ/Qは-99.87%です。
- Metso Oyjの収益YQ/Qは-99.87%です。
- MedinCell S.Aの収益YQ/Qは-99.87%です。
- Assureの収益YQ/Qは-99.85%です。
- Pritish Nandy Communications Ltdの収益YQ/Qは-99.85%です。
- JPMorgan Russian Securities Plcの収益YQ/Qは-99.83%です。
- Æterna Zentarisの収益YQ/Qは-99.81%です。
- American Resourcesの収益YQ/Qは-99.79%です。
- Sintex Plastics Technologyの収益YQ/Qは-99.79%です。
- Monarch Goldの収益YQ/Qは-99.73%です。
- AHAlifeの収益YQ/Qは-99.72%です。
- Mulvihill S Splitの収益YQ/Qは-99.72%です。
- Prabhat Telecoms (India)の収益YQ/Qは-99.67%です。